Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natrecor in Decompensated CHF
NCT00271557Phase 3Completed
- Sponsor
- Scios Inc.
- Start
- Jan 1997
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of nesiritide in congestive heart failure (CHF) (2 arms), sponsored by Scios Inc. Primary endpoint: Changes in symptoms and signs of CHF at 24 hours. Started Jan 1997; status: completed.
02
Drugs
nesiritide
03
Conditions
congestive heart failure (CHF)
Beyond the preview
Go deeper on NCT00271557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271557.